Biaoru Li | Personalized Medicine | Oncolog Oncopharm Research Achievement

Published on 21/10/2025 by Top Pharmaceutical

Dr. Biaoru Li | Personalized Medicine | Oncolog Oncopharm Research Achievement

Medical College of GA | United States

Dr. Biaoru Li is an accomplished leader in the fields of precision medicine, genomics, and personalized immunotherapy, with extensive experience spanning clinical hematology, oncology, and advanced molecular research. His expertise bridges the continuum from bio-specimen preparation to clinical application, integrating cutting-edge biobanking, primary cell sorting, single-cell identification, and functional genomics. Dr. Li’s research delves deeply into the cellular and molecular mechanisms that drive disease, with a particular focus on CD34 cells, erythroid cells, T-cells, and primary tumor cells. His work emphasizes the transformation of primary bio-specimens into powerful genomic insights through advanced technologies such as next-generation sequencing (NGS) and microarray analysis.A pioneer in precision medicine, Dr. Li has made substantial contributions to the development of personalized immunotherapy strategies and the integration of artificial intelligence into biomedical research. His ongoing projects include the design of AI-driven models that enhance diagnostic accuracy and therapeutic prediction for cancer and immune-related disorders. Dr. Li’s innovative research on single-cell RNA sequencing has opened new pathways for individualized treatment, offering a molecular-level understanding of disease heterogeneity.As an academic and clinical researcher, Dr. Li has established collaborations with hospitals and research institutions across the United States and Asia, promoting global scientific exchange and clinical translation. His scholarly impact is reflected in his numerous publications indexed in prestigious scientific databases such as SCI and Scopus, as well as his extensive citation record on Google Scholar and ORCID. Dr. Li’s editorial influence extends across 17 international editorial boards, where he contributes to advancing scientific standards in molecular medicine and clinical genomics.In addition to his academic achievements, Dr. Li has authored influential books, including Personalized Immunotherapy for Tumor Disease and Beyond and Personalized Therapy for PAH and Beyond, both of which underscore his leadership in developing targeted therapeutic frameworks. His membership in renowned professional societies, including the American Society of Hematology and the Royal Society of Medicine, underscores his commitment to advancing medical science and mentoring future researchers.

Profile: Orcid

Featured Publications

Li, S., & Li, B. (2025). Precision medicine related to landscape and architecture of tumor specimen. Japan Journal of Research.

Song, P., & Li, B. (2025). New generation of clinical epigenetics analysis and diagnosis for precision medicine. Diagnostics.

Palani, C. D., Smith, A., Cao, X., Li, B., Pace, B. S., & Starlard‐Davenport, A. (2025). Cholesterol‐conjugated miR‐29b induces fetal haemoglobin expression via γ‐globin promoter demethylation in the Townes mouse model for sickle cell anaemia. British Journal of Haematology.

Yang, Y., Chen, S., Li, W., Duan, J. C., Yuan, Y., Xie, V. S., & Li, B. (2024). STAT3 down-regulation for IL-2 inducing TIL-A clinical clue for spatial quantitative pathway analysis. AIMS Allergy and Immunology.

Li, B. (2024). Surgery and specimen biobanks—Tumor tissues and precision medicine. Journal of Surgery.

Li, B. (2024). Prediction, prevention, prognostic and personalized therapy of ovarian cancer—Biomarkers and precision medicine. Biomedical Journal of Scientific and Technical Research.

Yang, Y., Li, W., Chen, S., Yuan, Y., & Li, B. (2023). Spatial-timely quantitative network analysis for TGF-β pathway of tumor infiltrating lymphocytes. Journal of Cancer Science and Clinical Therapeutics.

Zhu, X., & Li, B. (Eds.). (2023). Epigenetics in cancer: Mechanisms and drug development – Volume II. Frontiers Research Topics.

Li, B. (2023). Personalized immunotherapy of patients: Defining by single-cell RNA-seq with artificial intelligence. Medical Research Archives.

Jl Clua-Espuny | Personalized Medicine | Best Researcher Award

Published on 10/09/2025 by Top Pharmaceutical

Assist Prof. Dr. Jl Clua-Espuny | Personalized Medicine | Best Researcher Award

Ebrictus Group at IDIAP Jordi Gol | Spain

Assist. Prof. Dr. JL Clua-Espuny is a distinguished academic and healthcare professional with extensive experience in medicine, primary healthcare, and medical education. He has served in various leadership and academic roles across prestigious institutions, including Universitat Rovira i Virgili, Universidad Miguel Hernández de Elche, and the Institut Català de la Salut. His expertise spans family medicine, health policy, and clinical research, with a strong commitment to improving patient care and medical training. Throughout his career, he has mentored numerous doctoral candidates, contributed to healthcare policy initiatives, and advanced research in cardiovascular diseases, primary care innovation, and public health strategies.

Publication Profile

Orcid

Education

Assist. Prof. Dr. JL Clua-Espuny holds multiple advanced degrees, including a Doctorate in Medicine and a Master’s in Primary Care from Universidad Miguel Hernández de Elche. He also completed specialized master’s programs in Health Economics and Healthcare Management from the University of Barcelona and advanced training in Quality Management at Universidad Autonoma de Barcelona and Fundació Avedis Donabedian. Additionally, he earned postgraduate diplomas in Primary Care Management and Quality Evaluation Methodologies and holds dual degrees in Medicine and Philosophy/Psychology from the University of Barcelona. His academic path reflects a dedication to integrating medical, administrative, and research excellence to improve healthcare delivery systems.

Experience

Assist. Prof. Dr. JL Clua-Espuny career spans healthcare, academia, and research. He served as Director of Primary Care at the Institut Català de la Salut, Vice-President of the Health Council in Tortosa, and Coordinator of Health Plans for the Catalan Health Service. In academia, he has been a professor and tutor at Universitat Rovira i Virgili and Universidad Miguel Hernández de Elche, guiding numerous doctoral and master’s theses. His research affiliations include the Institut Recerca IDIAP Jordi Gol. He has combined clinical practice, academic instruction, healthcare leadership, and policy planning, contributing significantly to primary care innovations and medical education reforms in Spain.

Awards and Honors

Assist. Prof. Dr. JL Clua-Espuny has received multiple honors for his contributions to medicine, education, and research. He earned the Premio Extraordinario de Doctorado for academic excellence and has been recognized for advancing primary healthcare research and education in Catalonia. His leadership roles in healthcare institutions and medical associations highlight his influence in shaping health policy and service delivery. He has been invited to collaborate in national and regional healthcare planning, reflecting his reputation as an expert in primary care management and cardiovascular health research. His mentorship of numerous doctoral theses further illustrates his commitment to academic excellence and professional development.

Research Focus

Assist. Prof. Dr. JL Clua-Espuny research centers on primary healthcare, cardiovascular disease prevention, public health interventions, and healthcare quality improvement. He has led and collaborated on projects investigating atrial fibrillation, ischemic stroke, heart failure, and healthcare service optimization. His work often bridges clinical practice with public health policy, emphasizing early detection, risk stratification, and health outcomes in community settings. He has contributed extensively to evaluating the economic impact of chronic diseases, vaccination strategies, and integrated care models. His multidisciplinary approach combines epidemiology, clinical research, and healthcare management to develop innovative strategies for improving patient outcomes and enhancing primary care systems.

Publication Top Notes

Estado de malnutrición como factor pronóstico de eventos cardiovasculares adversos mayores (MACE) en los pacientes con fibrilación auricular

Recent-onset atrial fibrillation: challenges and opportunities

Integrating Lung Ultrasound and the HEFESTOS Score in the Outpatient Heart Failure Management: A Prospective Cohort Study

Prediction of Major Adverse Cardiovascular Events in Atrial Fibrillation: A Comparison Between Machine Learning Techniques and CHA2DS2-VASc Score

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Abordaje extrahospitalario y hospitalario del ictus en fase aguda

Detección precoz de la fibrilación auricular a través de alteraciones en la onda P en el electrocardiograma (ECG) y la disfunción auricular en el ecocardiograma transtorácico (ETT) (póster)

Evidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)

Evidence Gaps and Lessons in Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)

The Predictive Potential of C-Peptide in Differentiating Type 1 Diabetes From Type 2 Diabetes in an Outpatient Population in Abu Dhabi.

Sex Disparities in the Direct Cost and Management of Stroke: A Population-Based Retrospective Study

Prognostic Significance of Lung Ultrasound for Heart Failure Patient Management in Primary Care: A Systematic Review

Conclusion

Given his extensive research supervision, academic leadership, healthcare experience, and contributions to primary care and public health research, Assist. Prof. Dr. JL Clua-Espuny is highly suitable for the Best Researcher Award. His decades of service, combined with scientific innovation, educational mentorship, and healthcare leadership, position him as a strong candidate. By expanding global research collaborations and enhancing the international dissemination of his work, he could further elevate his impact in the field.